SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending sharply upwards following exceptionally positive Phase 2 S-OLARIS trial data for sonelokimab in axial spondyloarthritis, which revealed "disease-modifying" potential and robust efficacy. The community is buzzing with expectations for significant upside, fueled by a major institutional buyback, strong financials, and the upcoming Investor Day, intensifying talks of a potential short squeeze and a "best-in-class" valuation.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is trending due to prevailing community bearishness surrounding new global tariffs and escalating geopolitical tensions, which, coupled with a crypto market downturn, has many anticipating a notable market correction.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending due to a recent filing that would allow Trump's trust to sell a significant amount of stock and includes an evergreen provision for future share issuance, sparking active community discussion and widespread concerns over potential dilution and the company's long-term valuation.

BlackRock Institutional Trust Company N.A. - iShares MSCI South Korea ETF

iShares MSCI South Korea ETF

The iShares MSCI South Korea ETF ($EWY) is trending at all-time highs, propelled by strong performance from its major semiconductor holdings, Samsung and SK Hynix, amid surging demand for AI-driven memory and anticipated DRAM shortages through 2027. The community is actively discussing its remarkable outperformance compared to global markets and its continued growth potential.

TOSHI

TOSHI is actively trending across the crypto community, driven by strong technical indicators pointing to an imminent breakout and a prevailing bullish sentiment for its role as a key memecoin within the Base ecosystem. Many investors are seizing current price levels, anticipating a substantial rally as altcoin season gains momentum.

Workday, Inc. engages in the provision of development of enterprise cloud applications for finance and human resources. It delivers financial management, human capital management and analytics applications designed for companies, educational institutions, and government agencies. The company was founded by David A. Duffield and Aneel Bhusri in 2005 and is headquartered in Pleasanton, CA.

Workday Inc - Ordinary Shares - Class A

Workday Inc

Workday is seeing significant conversation after a leadership change brought co-founder Aneel Bhusri back as CEO to spearhead its AI transformation, with recent earnings guidance and AI acquisitions sparking intense community debate over its growth prospects in a rapidly evolving SaaS landscape.

Dell Technologies, Inc. is a technology company, providing customers with a broad and innovative solution portfolio to help customers modernize their information technology (IT) infrastructure, address workforce transformation, and offer critical solutions that keep people and organizations connected. It operates through the following segments: Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment includes servers, networking, and storage, as well as services and third-party software and peripherals that are closely tied to the sale of ISG hardware. The CSG segment includes designs for commercial and consumer customers of desktops, thin client products, and notebooks. The company was founded by Michael Saul Dell in 1984 and is headquartered in Round Rock, TX.

Dell Technologies Inc - Ordinary Shares - Class C

Dell Technologies Inc

Dell Technologies is a trending topic ahead of its earnings report, driven by expectations of strong AI server demand and recent analyst upgrades, although community discussion highlights skepticism and accusations of manipulation surrounding some downgrades amidst concerns about rising memory prices.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems is trending due to significant new awards for its rugged AI-at-the-edge computing solutions supporting U.S. Navy aircraft and recent contracts in defense and commercial robotics, reinforcing its position in critical sectors like military and autonomous systems. The community is actively discussing the company's strong fundamentals, including its recent profitability and growing pipeline, alongside the potential for a short squeeze given its tight float as investors anticipate further lucrative defense contracts.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as digital video compact disc player, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

Taiwan Semiconductor is seeing significant attention after reporting blowout earnings, strong guidance, and an ambitious capital expenditure outlook that reaffirms its central role in the AI supercycle, with investors also closely monitoring ongoing U.S.-Taiwan trade discussions that could further impact global chip supply.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor (OPEN) is trending post-earnings as it navigates a substantial GAAP net loss, with community discussion sharply divided between optimism for its "Opendoor 2.0" strategy, including an AI-powered mortgage product and institutional accumulation, and skepticism over persistent unprofitability and the long-term viability of its iBuying model.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Chip Wilson said the board must be refreshed to empower a creative, brand-first experience.</li><li>He has nominated three independent directors to the board.</li><li>Wilson has called for the board to immediately declassify so that all directors are elected annually by shareholders. &nbsp;</li></ul>Lululemon founder Chip Wilson has launched a proxy fight by nominating three independent directors in an effort to remake the company’s board as the athletic-apparel retailer searches for a new chief executive.&nbsp;Wilson has also submitted a non-binding proposal calling for the board to immediately declassify, so that all directors are elected annually by shareholders.The Lululemon founder has nominated three candidates to the company's board, including former On Running co-CEO Marc Maurer, former ESPN Chief Marketing Officer Laura Gentile, and former Activision CEO Eric Hirshberg.He noted that CEO selection must follow a significant board change to ensure shareholders can trust that the right decision is made and that the new leader can succeed.“The recent CEO change announcement was the third total failure of board oversight, with no clear succession plan in place. Shareholders have no faith that this board can select and support the next CEO without input from a board with stronger product experience,” Wilson stated.“The Board must be refreshed so that a creative, brand-first experience is empowered,” he added.<h2 class="st-heading-2">CEO Departure Sparking Reset</h2>Earlier this month, Lululemon said its CEO, Calvin McDonald, will leave the company. The firm named its finance chief, Meghan Frank, and chief commercial officer, André Maestrini, as co-interim CEOs.The reset at retailers is becoming a sector norm as U.S. President Donald Trump’s tariffs have been hurting sales and eating into profits at several top retailers and wholesalers. Firms have also been seeing consumer demand slow as price pressures continue to weigh on consumers' pockets. Firms from Nestle and Walmart to Coty and Coca-Cola have all changed their CEOs this year.Shares in Lululemon have fallen nearly 44% so far in 2025.Get updates to this developing story <a href="https://stocktwits.com/news-articles/markets/equity/lululemon-founder-launches-proxy-fight-to-change-baord/cL75M5PREx2">directly on Stocktwits.</a> &nbsp;

 A Lululemon corporate logo hangs on the front of their store in Brookfield Place on June 21, 2023, in New York City. (Photo by Gary Hershorn/Getty Images)

Lululemon Founder Targets Board Change Ahead Of CEO Search

The proposal seeks to make boardroom revisions before the athletic-apparel company chooses a new CEO. 

Equity

The proposal seeks to make boardroom revisions before the athletic-apparel company chooses a new CEO

<ul class="summary-bullets"><li>Biogen will obtain exclusive worldwide rights to Vanqua’s investigational drug that targets a protein involved in inflammatory responses.</li><li>Vanqua will receive $70 million upfront payments and will be eligible to receive up to $990 million in milestone payments.</li><li>Biogen will lead all future development, manufacturing, and commercialization efforts for the experimental drug.&nbsp; &nbsp;</li></ul>Biogen Inc. (BIIB) on Friday announced a license agreement with Vanqua Bio granting it exclusive worldwide rights to the latter’s preclinical drug candidate targeting a range of inflammatory disorders.Under the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.biogen.com/news-releases/news-release-details/biogen-licenses-oral-c5ar1-antagonist-vanqua-bio-expand">deal</a>, Biogen will obtain exclusive worldwide rights to Vanqua’s investigational drug that targets a protein involved in inflammatory responses.<h2 class="st-heading-2">Terms Of The Deal</h2>Vanqua will receive $70 million in upfront payments and be eligible to receive up to $990 million in milestone payments, in addition to tiered royalties on potential net sales, as per the agreement. Biogen will lead all future development, manufacturing, and commercialization efforts of the experimental drug.Jane Grogan, Executive Vice President and Head of Research at Biogen, said that advancing the program will enable it to deepen focus on immunological diseases.Biogen expects to file an application with the U.S. Food and Drug Administration for approval of the candidate in 2027, if results remain supportive. In preclinical studies, the program demonstrated activity as well as a safety and tolerability profile supportive of advancing it into clinical development, the company noted.Last year, Biogen also acquired privately held Human Immunology Biosciences for up to $1.8 billion to expand its immunology portfolio.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2><a href="https://stocktwits.com/symbol/BIIB">BIIB stock</a> rose 1% on Friday morning at the time of writing. On Stocktwits, retail sentiment around BIIB stayed within the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘low’ levels.<figure class="image"><img style="aspect-ratio:620/59;" src="data:image/png;base64,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" width="620" height="59" alt="BIIB's Sentiment Meter and Message Volume as of 11:30 a.m. ET on Oct. 24, 2025 | Source: Stocktwits"><figcaption>BIIB's Sentiment Meter and Message Volume as of 11:30 a.m. ET on Oct. 24, 2025 | Source: Stocktwits</figcaption></figure>According to Koyfin data, 16 of the 35 analysts covering Biogen rate it ‘Buy’ or higher, while 19 rate it ‘Hold’. The stock has an average price target of $172.55, representing a potential upside of about 14%.BIIB stock is down by 1% this year and by about 18% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-to-acquire-adverum-biotechnologies/cLGJ8N0R3tc">Eli Lilly To Acquire Adverum Biotechnologies</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration the logo of Biogen is seen on a smartphone with the FDA logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)  

Biogen Licenses Vanqua Bio’s Immunology Drug In $1.06B Deal

Biogen will lead all future development, manufacturing, and commercialization efforts for the experimental drug. 

<ul class="summary-bullets"><li>The Pennsylvania-headquartered company raised its full-year net sales guidance to $3.06 billion to $3.07 billion, up from $3.04 billion to $3.06 billion.&nbsp;</li><li>The company is banking on strong demand for its high-value product (HVP) components used in GLP-1 drugs for weight loss and diabetes management.&nbsp;</li><li>For Q3, West Pharmaceutical reported adjusted and diluted EPS of $1.92, compared to $1.85 in the same period last year.&nbsp; &nbsp;</li></ul>Shares of West Pharmaceutical Services (WST) soared 12% on Thursday afternoon after the company increased its full-year earnings guidance after its third-quarter earnings beat Wall Street expectations.The Pennsylvania-headquartered company, which manufactures packaging components and delivery systems for injectable drugs and healthcare products, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investor.westpharma.com/news-releases/news-release-details/west-reports-third-quarter-2025-results">raised</a> its full-year net sales guidance to $3.06 billion to $3.07 billion, up from $3.04 billion to $3.06 billion.It also hiked its full-year adjusted earnings per share (EPS) outlook to $7.06 to $7.11, up from $6.65 to $6.85, citing strong demand for its high-value product (HVP) components used in GLP-1 drugs for weight loss and diabetes regulation. In Q3, HVP components accounted for 48% of the company's total net sales.The firm, however, flagged that it continues to anticipate $15 million to $20 million in tariff-related costs this year.<h2 class="st-heading-2">CEO Remarks</h2>Chief Executive Eric M. Green stated that several factors drove HVP component sales in Q3. “First, elastomers for GLP-1s had strong growth and now account for 9% of total company sales. We benefit from our longstanding relationships as we partner with our customers in this market, supporting them as they expand their GLP-1 franchises…We expect this market to continue to evolve as there are a number of new early-stage trials seeking to expand the range of indications and treatments using GLP-1s,” Green said.He added that the company, which includes weight-loss drugmakers Eli Lilly and Novo Nordisk among its customers, is also collaborating with customers who are launching new GLP-1 molecules and generics.<h2 class="st-heading-2">Third Quarter Earnings</h2>For the third quarter (Q3), West Pharmaceutical reported adjusted and diluted EPS of $1.96, compared to $1.85 in the same period last year, and above an analyst estimate of $1.68, according to data from Fiscal AI. Net sales increased 7.7% year-over-year to $804.6 million in the quarter.The company reported a 16.3% increase in net sales of its HVP components to $390 million in the quarter. Contract-manufactured products segment net sales, meanwhile, rose 8% to $157.1 million, driven by increased sales of self-injection devices for obesity and diabetes.Evercore ISI analyst Daniel Markowitz raised the firm's price target on West Pharmaceutical to $390 from $350 while keeping an ‘Outperform’ rating on the shares following the earnings call.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/WST">WST stock</a> improved from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:619/59;" src="data:image/png;base64,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" width="619" height="59" alt="WST's Sentiment Meter and Message Volume as of 2:15 p.m. ET on Oct. 23, 2025 | Source: Stocktwits"><figcaption>WST's Sentiment Meter and Message Volume as of 2:15 p.m. ET on Oct. 23, 2025 | Source: Stocktwits</figcaption></figure>WST stock is down by 5% this year but has risen over 8% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/staar-surgical-stock-rises-after-adjournment-of-stockholders-meeting-to-discuss-proposed-merger-with-alcon/cLG4FXDR3rj">STAAR Surgical Stock Rises After Adjournment Of Stockholders’ Meeting To Discuss Proposed Merger With Alcon</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration a West Pharmaceutical Services logo is seen on a mobile phone screen in front of a graph. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

WST Stock Soars After Company Raises Full-Year Guidance On Strong Demand For GLP-1 Drug Components

The Pennsylvania-headquartered company raised its full-year net sales guidance to $3.06 billion to $3.07 billion, up from $3.04 billion to $3.06 billion. 

Shares of Humana (HUM) rose 3% on Thursday afternoon after the company affirmed its full-year earnings per share guidance provided in July.The insurer stated that it expects adjusted earnings per common share of $17 for the year ending Dec. 31, 2025, and diluted earnings per share of $13.77.The firm also stated that its preliminary 2026 Medicare Advantage (MA) Star Ratings align with the assumptions in its financial planning. As a result, there is no change to the incremental earnings potential for 2025 to 2028. The ratings data provided by the Centers for Medicare and Medicaid Services was inadvertently accessible on CMS Plan Finder for a brief period on Oct. 1, 2025, the company stated.CMS assigns a star rating to Medicare Advantage plans, ranging from one to five, with five being the highest rating. Beneficiaries can use this data to help choose plans, and insurance companies can receive government bonus payments for higher ratings.Humana has about 20% of its members currently enrolled in Medicare plans rated four stars and above for 2026, and 14% of members in 4.5-star plans for 2026, it said.“Based on all information available to date, the company remains confident in its 2026 Individual MA pricing and benefit design, including the expectation that it will double individual MA pre-tax margin in 2026 (excluding Stars), and believes it is positioned to return to membership growth in 2026,” the firm <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/Archives/edgar/data/49071/000004907125000048/hum-20251002.htm">said</a>.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/HUM">HUM stock</a> rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:625/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_02_at_1_48_22_PM_png_d2e549fd89.webp" alt="HUM's Sentiment Meter and Message Volume as of 2 p.m. ET on Oct. 02, 2025 | Source: Stocktwits" width="625" height="62"><figcaption>HUM's Sentiment Meter and Message Volume as of 2 p.m. ET on Oct. 02, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user reported selling their holdings in Humana, citing excessive volatility.<stembedurl>https://stocktwits.com/Felo3179/message/630807403</stembedurl>HUM stock has risen 3% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/immuron-stock-rallies-after-ceo-dismisses-us-pharma-tariff-impact/chCrSSWR3f5">Immuron Stock Rallies After CEO Dismisses US Pharma Tariff Impact, Provides Positive Pipeline Updates</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The MyHumana app page is displayed on a smartphone in the Apple App Store in front of the Humana Inc logo on October 30, 2024 in Chongqing, China. (Photo by Cheng Xin/Getty Images)

Humana Stock Rises After Insurer Reaffirms Full-Year Earnings Guidance

The firm also stated that its preliminary 2026 Medicare Advantage Star Ratings align with the assumptions in its financial planning, and as a result, there is no change to the incremental earnings potential for 2025 to 2028.

Current Price	$17.97
Prev Close	$17.84
Open	$17.81
Dividend Yield	N/A
50-Day Moving Average	$17.91
Beta	N/A
Avg. Volume	27,177.50
PE Ratio	N/A

52-Week High	$19.45
52-Week Low	$17.38
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

XRMI
Global X S&P 500 Risk Managed Income

Feed

News

Sentiment

Fundamentals

Info

Latest XRMI News

XRMIGlobal X S&P 500 Risk Managed Income